Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016.
Immuno-oncology has changed the landscape of cancer treatment in recent years. Immune checkpoint inhibitors (ICI) have shown survival advantage with long term remissions in a variety of cancers. However, there is another approach to harnessing the power of the immune system in combating cancer: the adoptive cell therapy (ACT) strategy. Although ACT is restricted to small specialized centres and has yet to deliver as much success as ICI, some important results were presented at this year's ASCO meeting. Important lessons have been learned from these studies, including the prospects and challenges ahead. In this editorial, we summarize the important studies on ACT presented at the ASCO 2016 meeting and discuss the way forward.
Royal Free Hospital, Pond Street, London NW3 2QG, UK.; Astrazeneca PLC, Cambridgeshire SG8 6HB, UK.
Leila
L
Khoja
Department of Haemato-Oncology, Nobel Hospital, Kathmandu 21034, Nepal.
Bishal
B
Gyawali
adoptive cell therapy; chimeric antigen receptor-modified T cells; immuno-oncology; immunotherapy; tumour infiltrating lymphocytes